- Home
- ALF vs EDIT Comparison
ALF vs EDIT Comparison
Compare ALF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- EDIT
- Stock Information
- Founded
- ALF 2024
- EDIT 2013
- Country
- ALF United States
- EDIT United States
- Employees
- ALF N/A
- EDIT N/A
- Industry
- ALF
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALF
- EDIT Health Care
- Exchange
- ALF NYSE
- EDIT Nasdaq
- Market Cap
- ALF 360.5M
- EDIT 327.0M
- IPO Year
- ALF 2024
- EDIT 2016
- Fundamental
- Price
- ALF $10.03
- EDIT $3.22
- Analyst Decision
- ALF
- EDIT Buy
- Analyst Count
- ALF 0
- EDIT 13
- Target Price
- ALF N/A
- EDIT $9.38
- AVG Volume (30 Days)
- ALF 40.4K
- EDIT 2.1M
- Earning Date
- ALF 01-01-0001
- EDIT 11-04-2024
- Dividend Yield
- ALF N/A
- EDIT N/A
- EPS Growth
- ALF N/A
- EDIT N/A
- EPS
- ALF N/A
- EDIT N/A
- Revenue
- ALF N/A
- EDIT $61,759,000.00
- Revenue This Year
- ALF N/A
- EDIT N/A
- Revenue Next Year
- ALF N/A
- EDIT N/A
- P/E Ratio
- ALF N/A
- EDIT N/A
- Revenue Growth
- ALF N/A
- EDIT 150.95
- 52 Week Low
- ALF $9.96
- EDIT $2.70
- 52 Week High
- ALF $10.25
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- EDIT 49.77
- Support Level
- ALF N/A
- EDIT $2.70
- Resistance Level
- ALF N/A
- EDIT $3.40
- Average True Range (ATR)
- ALF 0.00
- EDIT 0.25
- MACD
- ALF 0.00
- EDIT 0.02
- Stochastic Oscillator
- ALF 0.00
- EDIT 49.09
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.